Download pdf
Mass spectrometry imaging metabolomics reveals the metabolic spatial heterogeneity in gastric cancer
- 1 Mulgrave School
* Author to whom correspondence should be addressed.
Abstract
Gastric cancer is the second leading cause of cancer-related deaths in the world. It is estimated that gastric cancer would cause 12,000,000 deaths by 2030. Gastric cancer diagnosis in its early stages is often challenging due to the lack of specific symptoms, while early diagnosis is pivotal to patient survival. The discovery of tumor-specific biomarkers plays a crucial role in effectively diagnosing gastric cancer. Metabolomics-based approaches provide qualitative and quantitative measurements of the metabolic signatures that are unique to cancerous tissue. Recently, mass spectrometry imaging (MSI)--based metabolomics enables untargeted investigation of molecular species concerning spatial distribution across tissues, elucidating the heterogeneity of gastric cancer. In this study, a computational imaging segmentation-based pipeline that analyses the spatial distribution of metabolite for gastric cancer using MSI metabolomics data is developed, which leads to the discovery of differentially expressed metabolites and the identification of biomarkers across different tissue subtypes in gastric cancer.
Keywords
Metabolomics, gastric cancer, biomarker, image segmentation
[1]. Wang, J. et al. Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 28, 2865–2877 (2022).
[2]. Sitarz, R. et al. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag. Res. 10, 239–248 (2018).
[3]. Topi, S. et al. Gastric Cancer in History: A Perspective Interdisciplinary Study. Cancers 12, 264 (2020).
[4]. Maconi, G., Manes, G. & Porro, G. B. Role of symptoms in diagnosis and outcome of gastric cancer. World J. Gastroenterol. WJG 14, 1149–1155 (2008).
[5]. Zali, H., Rezaei-Tavirani, M. & Azodi, M. Gastric cancer: prevention, risk factors and treatment. Gastroenterol. Hepatol. Bed Bench 4, 175–185 (2011).
[6]. Layke, J. C. & Lopez, P. P. Gastric cancer: diagnosis and treatment options. Am. Fam. Physician 69, 1133–1140 (2004).
[7]. Kadam, W., Wei, B. & Li, F. Metabolomics of Gastric Cancer. in Cancer Metabolomics: Methods and Applications (ed. Hu, S.) 291–301 (Springer International Publishing, Cham, 2021). doi:10.1007/978-3-030-51652-9_20.
[8]. Ursu, Ștefan et al. Role of Metabolomics in Pathogenesis and Prompt Diagnosis of Gastric Cancer Metastasis—A Systematic Review. Diagnostics 13, 3401 (2023).
[9]. Jayavelu, N. D. & Bar, N. S. Metabolomic studies of human gastric cancer: Review. World J. Gastroenterol. WJG 20, 8092–8101 (2014).
[10]. Antonio, M. J., Zhang, C. & Le, A. Different Tumor Microenvironments Lead to Different Metabolic Phenotypes. in The Heterogeneity of Cancer Metabolism (ed. Le, A.) 137–147 (Springer International Publishing, Cham, 2021). doi:10.1007/978-3-030-65768-0_10.
[11]. Gowda, G. A. N. & Raftery, D. NMR Based Metabolomics. Adv. Exp. Med. Biol. 1280, 19–37 (2021).
[12]. Sun, C. et al. Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer. Nat. Commun. 14, 2692 (2023).
[13]. Yuan, L.-W., Yamashita, H. & Seto, Y. Glucose metabolism in gastric cancer: The cutting-edge. World J. Gastroenterol. 22, 2046–2059 (2016).
[14]. In, H. et al. Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 31, 1426–1432 (2022).
[15]. Rae Buchberger, A., DeLaney, K., Johnson, J. & Li, L. Mass Spectrometry Imaging: A Review of Emerging Advancements and Future Insights. Anal. Chem. 90, 240–265 (2018).
[16]. Li, S. et al. Predicting Network Activity from High Throughput Metabolomics. PLOS Comput. Biol. 9, e1003123 (2013).
[17]. NAD(P)‐dependent steroid dehydrogenase‐like protein and neutral cholesterol ester hydrolase 1 serve as novel markers for early detection of gastric cancer identified using quantitative proteomics - Xiao - 2021 - Journal of Clinical Laboratory Analysis - Wiley Online Library. https://onlinelibrary.wiley.com/doi/full/10.1002/jcla.23652.
[18]. Wroblewski, L. E., Peek, R. M. & Wilson, K. T. Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk. Clin. Microbiol. Rev. 23, 713–739 (2010).
[19]. Kamisago, S. et al. Role of sulfatides in adhesion of Helicobacter pylori to gastric cancer cells. Infect. Immun. 64, 624–628 (1996).
[20]. Ren, Z. et al. Lysophosphatidic acid induces the migration and invasion of SGC-7901 gastric cancer cells through the LPA2 and Notch signaling pathways. Int. J. Mol. Med. 44, 67–78 (2019).
[21]. Lim, S.-C., Parajuli, K. R., Duong, H.-Q., Choi, J. E. & Han, S. I. Cholesterol induces autophagic and apoptotic death in gastric carcinoma cells. Int. J. Oncol. 44, 805–811 (2014).
[22]. Mayengbam, S. S., Singh, A., Pillai, A. D. & Bhat, M. K. Influence of cholesterol on cancer progression and therapy. Transl. Oncol. 14, 101043 (2021).
[23]. Tamura, T., Inagawa, S., Hisakura, K., Enomoto, T. & Ohkohchi, N. Evaluation of serum high-density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. J. Gastroenterol. Hepatol. 27, 1635–1640 (2012).
Cite this article
Wang,C. (2024). Mass spectrometry imaging metabolomics reveals the metabolic spatial heterogeneity in gastric cancer . Theoretical and Natural Science,49,39-45.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).